Becton Dickinson and (NYSE:BDX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.
According to Zacks, “In the last year, Becton, Dickinson and Company, popularly known as BD, has outperformed the broader industry. BD recently completed the acquisition of C. R. Bard. The company will establish a new segment — BD Interventional in which Bard will be integrated. The acquisition is viewed as a strategic one which will generate benefits from complementary businesses and geographical expansion. In recent past, BD announced that it will divest its soft tissue core needle biopsy products for $100 million to Merit Medical. On the flip side, lackluster performance by the Medical segment, from the prior year period is a concern. Performance in the segment was affected by sluggishness in the Medication Management Solutions and Pharmaceutical Systems units in the United States. BD temporarily paused shipments of its insulin infusion sets. The voluntary recall of Barricor blood collection tubes in the recent past also adds to our woes.”
Other research analysts have also issued reports about the stock. Wells Fargo & Co began coverage on shares of Becton Dickinson and in a research note on Friday, September 22nd. They issued an “outperform” rating and a $225.00 price target for the company. Evercore ISI began coverage on shares of Becton Dickinson and in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 price target for the company. Argus increased their price target on shares of Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research note on Thursday, December 14th. They noted that the move was a valuation call. Citigroup upgraded shares of Becton Dickinson and from a “sell” rating to a “neutral” rating in a research note on Friday, January 5th. Finally, KeyCorp began coverage on shares of Becton Dickinson and in a research note on Friday, January 5th. They issued an “overweight” rating and a $260.00 price target for the company. Five equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $230.20.
Shares of Becton Dickinson and (BDX) traded up $0.60 during trading on Friday, hitting $226.42. 825,797 shares of the company traded hands, compared to its average volume of 1,643,650. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58. The company has a market cap of $52,070.00, a price-to-earnings ratio of 48.69, a price-to-earnings-growth ratio of 1.70 and a beta of 1.07. Becton Dickinson and has a 52 week low of $169.19 and a 52 week high of $229.68.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.37 by $0.03. The company had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. Becton Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. Becton Dickinson and’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same period last year, the business earned $2.12 EPS. equities analysts anticipate that Becton Dickinson and will post 10.89 EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the business. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in Becton Dickinson and by 55.8% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after purchasing an additional 240 shares in the last quarter. Harfst & Associates Inc. increased its stake in Becton Dickinson and by 46.4% during the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after purchasing an additional 221 shares in the last quarter. Harvest Fund Management Co. Ltd increased its stake in Becton Dickinson and by 82.8% during the 2nd quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock valued at $146,000 after purchasing an additional 338 shares in the last quarter. Acrospire Investment Management LLC increased its stake in Becton Dickinson and by 259.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock valued at $162,000 after purchasing an additional 600 shares in the last quarter. Finally, Valeo Financial Advisors LLC bought a new stake in Becton Dickinson and during the 3rd quarter valued at about $191,000. Institutional investors and hedge funds own 75.53% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://transcriptdaily.com/2018/01/12/zacks-investment-research-lowers-becton-dickinson-and-bdx-to-hold.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.